阿普米司特治疗银屑病关节炎患者主要心脏事件风险
基于美国MarketScan数据库的队列研究纳入68 678例接受阿普米司特、TNF抑制剂生物制剂、IL-17或IL-12/23生物制剂、传统DMARDs或糖皮质激素治疗的银屑病关节炎患者,评估心肌梗死、卒中和血运重建风险。结果显示所有治疗下事件发生率均较低,阿普米司特未显示急性心血管危害信号,未与这些严重心脏事件风险实质性增加相关。
要点
- 阿普米司特治疗者心肌梗死发生率为2.5/1000人年,卒中1.6/1000人年,血运重建3.3/1000人年。
- TNF抑制剂生物制剂心肌梗死发生率最低(1.4/1000人年),其他治疗包括阿普米司特为1.8-3.8/1000人年。
- 所有治疗下卒中和血运重建发生率相似,阿普米司特未显示急性心血管危害信号。
核心结论
- 在接受系统治疗的银屑病关节炎患者中,阿普米司特未显示急性心血管危害信号,未与心肌梗死、卒中或血运重建风险实质性增加相关。
研究设计与样本
- 基于美国MarketScan数据库的队列研究,纳入68 678例接受阿普米司特、TNF抑制剂生物制剂、IL-17或IL-12/23生物制剂、传统DMARDs或糖皮质激素治疗的银屑病关节炎患者,队列进入时间为2014年3月21日后首次使用研究药物之日。
主要发现
- 共识别292例心肌梗死、151例卒中和475例血运重建病例。
- 心肌梗死发生率在TNF抑制剂生物制剂使用者中最低(1.4/1000人年),其他治疗包括阿普米司特为1.8-3.8/1000人年。
- 卒中发生率各治疗为0.1-1.6/1000人年,血运重建为3.1-5.1/1000人年。
- 阿普米司特的心肌梗死发生率为2.5/1000人年,卒中为1.6/1000人年,血运重建为3.3/1000人年。
临床怎么用
- 对于接受阿普米司特治疗的银屑病关节炎患者,现有数据未提示急性心血管风险增加,临床可参考此安全性信息。
局限性
- 事件数量较少(心肌梗死292例、卒中151例、血运重建475例),可能限制统计效能。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: People with PsA are at increased risk of cardiovascular disease. The objective of this study was to quantify the risk of myocardial infarction (MI), stroke and revascularizations in people with apremilast-treated PsA compared with patients receiving other PsA treatments. METHODS: We conducted a cohort study of 68 678 patients with PsA treated with apremilast, TNF inhibitor (TNF-i) biologics, IL-17 or -12/23 biologics, conventional DMARDs or CS in the United States MarketScan database. Cohort entry was date of first study drug after 21 March 2014. Cases were patients with MI, stroke or revascularization. We calculated incidence rates (IRs) and incidence rate ratios for each outcome by exposure. RESULTS: We identified 292 MI, 151 stroke and 475 revascularizations cases. IRs for MI were lowest for users of TNF-i biologics [1.4 per 1000 person-years (PY)] and similar for all other treatments, including apremilast, ranging from 1.8 to 3.8 per 1000 PY. IRs were similar for all treatments for both stroke (0.1-1.6 per 1000 PY) and revascularization (3.1-5.1 per 1000 PY). IRs for apremilast were 2.5 per 1000 PY for MI, 1.6 per 1000 PY for stroke and 3.3 per 1000 PY for revascularization. CONCLUSION: In patients with treated PsA, IRs of MI, stroke and revascularization were low for all systemic treatments evaluated. Although the number of events was small, apremilast exposure did not signal potential acute cardiovascular harm and was not associated with a material increase in the risk of these serious cardiac events.
引用
- Persson R, Hagberg KW, Qian Y, et al. The risks of major cardiac events among patients with psoriatic arthritis treated with apremilast, biologics, DMARDs or corticosteroids. Rheumatology (Oxford). 2021. PMID: 33159794. doi:10.1093/rheumatology/keaa683
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。